News & Media

Hierotope® platform enables design and engineering of next-generation antibody-based therapies Strengthens commitment to nephrology and other hard-to-treat diseases Tokyo, Japan and Waltham, Mass., July 11, 2018 - Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Visterra, Inc. (Visterra) announce that they have entered into a definitive merger agreement pursuant to which Otsuka will acquire

                      Tokyo, Japan and Deerfield, Ill., U.S., May 23, 2018 - Otsuka Pharmaceutical Company, Ltd. (Otsuka) and Lundbeck announce that the two companies’ third clinical Phase 3 study of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type will commence in June.  Approximately 300 patients are expected to be enrolled in this

Leading pharmaceutical companies, advocacy organizations, academic institutions, and care services companies join forces to create a new model for bringing patient and caregiver voices into therapy development, the drug review process, policymaking, and care. May 21, 2018 – Today, UsAgainstAlzheimer’s is launching the first of its kind Alzheimer’s Disease Patient and Caregiver Engagement

Gettysburg, Pa. (April 29, 2018) — Nearly 3.4 million adults, or 1.1% of the U.S. population, are affected by schizophrenia.1,2 As a chronic, relapsing condition, those who have schizophrenia may experience worsening of symptoms, repeat hospital stays, and a decrease in medication efficacy – which may contribute to costly care.3,4,5,6 Additionally, past relapses may predict an increased